HCV NS5A Inhibitor Compounds Targeting Viral Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Hepatitis C virus (HCV) infection, particularly those targeting the NS5A protein, have suboptimal success rates and cause significant side effects, and there is a need for compounds that can selectively inhibit HCV viral replication to address the genetic heterogeneity and mutation propensity of the virus.
Innovation Solution
Development of specific antiviral compounds, represented by Formula (I), which are designed to inhibit the function of the NS5A protein, comprising a pharmaceutically acceptable salt with specific structural features that include various substituents and functional groups, allowing for selective inhibition of HCV viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard therapies (pegylated-interferon and ribavirin) are used to treat HCV, then viral replication is inhibited to some extent, but success rate is non-optimal and numerous side effects occur
Solution Approach 1:
The patent modifies the chemical structure of NS5A inhibitors by changing parameters such as the imidazole ring substitution patterns (e.g., 1H-imidazole-4-yl versus 1H-imidazole-2-yl groups), linker lengths, and side chain configurations to achieve optimized viral replication inhibition with reduced toxicity. This structural parameter optimization resolves the contradiction between efficacy and side effects.
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional moieties (e.g., bithiophene cores, imidazole substituents, pyrrolidine linkers, and carboxylic acid groups) to create NS5A inhibitors that achieve superior viral replication inhibition compared to single-component therapies, while the composite nature allows for tailored pharmacological profiles that reduce side effects.
2Reliability
If HCV treatment targets are selected to address viral replication, then viral inhibition is achieved, but genetic heterogeneity and mutation propensity reduce treatment effectiveness
Solution Approach 1:
The patent divides the HCV NS5A protein into functional regions (e.g., conserved domains versus variable regions) and designs inhibitors that target conserved structural motifs, thereby achieving viral inhibition that is less susceptible to escape mutations. The segmentation approach allows the inhibitor to bind to invariant features of the protein regardless of viral genotype variations.
Solution Approach 2:
The NS5A inhibitors described possess multi-functional characteristics that enable them to inhibit viral replication across different HCV genotypes and subtypes. The compounds can bind to NS5A from various genotypes (1b, 2a, 3a, 4a, etc.) with comparable efficacy, providing universal coverage that addresses genetic heterogeneity and prevents treatment failure due to viral adaptation.
Data Source
AI summary
This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.